1. Home
  2. AIRJ vs XERS Comparison

AIRJ vs XERS Comparison

Compare AIRJ & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIRJ
  • XERS
  • Stock Information
  • Founded
  • AIRJ N/A
  • XERS 2005
  • Country
  • AIRJ United States
  • XERS United States
  • Employees
  • AIRJ N/A
  • XERS N/A
  • Industry
  • AIRJ
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIRJ
  • XERS Health Care
  • Exchange
  • AIRJ NYSE
  • XERS Nasdaq
  • Market Cap
  • AIRJ 451.2M
  • XERS 526.3M
  • IPO Year
  • AIRJ N/A
  • XERS 2018
  • Fundamental
  • Price
  • AIRJ $8.11
  • XERS $3.63
  • Analyst Decision
  • AIRJ Strong Buy
  • XERS Buy
  • Analyst Count
  • AIRJ 1
  • XERS 3
  • Target Price
  • AIRJ $12.00
  • XERS $4.87
  • AVG Volume (30 Days)
  • AIRJ 62.9K
  • XERS 1.6M
  • Earning Date
  • AIRJ 02-26-2025
  • XERS 03-05-2025
  • Dividend Yield
  • AIRJ N/A
  • XERS N/A
  • EPS Growth
  • AIRJ N/A
  • XERS N/A
  • EPS
  • AIRJ 4.07
  • XERS N/A
  • Revenue
  • AIRJ N/A
  • XERS $187,361,000.00
  • Revenue This Year
  • AIRJ N/A
  • XERS $24.64
  • Revenue Next Year
  • AIRJ N/A
  • XERS $19.04
  • P/E Ratio
  • AIRJ $1.98
  • XERS N/A
  • Revenue Growth
  • AIRJ N/A
  • XERS 22.72
  • 52 Week Low
  • AIRJ $4.94
  • XERS $1.69
  • 52 Week High
  • AIRJ $49.11
  • XERS $3.87
  • Technical
  • Relative Strength Index (RSI)
  • AIRJ 48.38
  • XERS 58.70
  • Support Level
  • AIRJ $7.22
  • XERS $3.47
  • Resistance Level
  • AIRJ $8.48
  • XERS $3.78
  • Average True Range (ATR)
  • AIRJ 0.63
  • XERS 0.16
  • MACD
  • AIRJ -0.03
  • XERS 0.03
  • Stochastic Oscillator
  • AIRJ 45.05
  • XERS 69.84

About AIRJ MONTANA TECHNOLOGIES CORP

AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: